Trial Information
Inclusion Criteria:
- patients less than 61 years of age
- Durie Salmon stage II or III
- written and informed consent
Exclusion Criteria:
- Prior treatment for myeloma
- ECOG performance score of 4
- Positive HIV test
- Chronic respiratory disease (DLco < 60%)
- Systolic ejection fraction < 50%
- Pregnant or nursing women
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Overall survival (from randomistion) of the 2 groups at 5 years
Principal Investigator
abderrahman abdelkefi
Investigator Role:
Principal Investigator
Investigator Affiliation:
Centre National de Greffe de Moelle Osseuse
Authority:
Tunisia: Ministère de la Santé Publique
Study ID:
MM01
NCT ID:
NCT00207805
Start Date:
May 2003
Completion Date:
Related Keywords:
- Multiple Myeloma
- Multiple Myeloma
- Neoplasms, Plasma Cell